In vivo modulation of somatomedin receptor sites

Effects of growth hormone treatment of hypopituitary children

Ronald (Ron) Rosenfeld, S. F. Kemp, S. Gaspich, R. L. Hintz

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We have previously demonstrated that somatomedin (SM) can induce the loss of specific SMC receptors on cultured IM-9 lymphocytes in a time- and concentration-dependent manner. To investigate the acute regulation of SM binding under in vivo conditions, we have evaluated SM receptors on circulating mononuclear cells obtained from 12 hypopituitary dwarfs before and after 4 days of human GH administration (0.1 U/kg.day). Plasma SM levels, measured by radioreceptor assay, rose from 0.37 ± 0.08 U/ml (mean ± SEM) to 1.00 ± 0.10 (P <0.001). Concomitantly, specific binding of [125I]SMC to 50 x 106 mononuclear cells/ml fell from 13.61 ± 0.97% to 10.40 ± 0.85% (P <0.02). The decrease in specific binding was predominantly secondary to a reduced number of SMC receptor sites per cell, with no alteration in receptor affinity. Overall, a significant inverse correlation was observed between plasma SM levels and mononuclear cellular binding of [125I]SMC (P <0.001). The data demonstrate that treatment of hypopituitary dwarfs with conventional therapeutic doses of human GH results in significant acute increases in plasma SM levels in the majority of subjects, with a reciprocal decline in the specific binding of [125I]SMC. We conclude that SM, like insulin, is capable of regulating homologous receptor concentrations under both in vitro and in vivo conditions.

Original languageEnglish (US)
Pages (from-to)759-764
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume52
Issue number4
StatePublished - 1981
Externally publishedYes

Fingerprint

Somatomedin Receptors
Somatomedins
Growth Hormone
Modulation
Plasmas
Therapeutics
Radioligand Assay
Lymphocytes
Assays
Insulin
Scanning electron microscopy

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

In vivo modulation of somatomedin receptor sites : Effects of growth hormone treatment of hypopituitary children. / Rosenfeld, Ronald (Ron); Kemp, S. F.; Gaspich, S.; Hintz, R. L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 52, No. 4, 1981, p. 759-764.

Research output: Contribution to journalArticle

Rosenfeld, Ronald (Ron) ; Kemp, S. F. ; Gaspich, S. ; Hintz, R. L. / In vivo modulation of somatomedin receptor sites : Effects of growth hormone treatment of hypopituitary children. In: Journal of Clinical Endocrinology and Metabolism. 1981 ; Vol. 52, No. 4. pp. 759-764.
@article{513db237b3f8431c959f644cdc0d0085,
title = "In vivo modulation of somatomedin receptor sites: Effects of growth hormone treatment of hypopituitary children",
abstract = "We have previously demonstrated that somatomedin (SM) can induce the loss of specific SMC receptors on cultured IM-9 lymphocytes in a time- and concentration-dependent manner. To investigate the acute regulation of SM binding under in vivo conditions, we have evaluated SM receptors on circulating mononuclear cells obtained from 12 hypopituitary dwarfs before and after 4 days of human GH administration (0.1 U/kg.day). Plasma SM levels, measured by radioreceptor assay, rose from 0.37 ± 0.08 U/ml (mean ± SEM) to 1.00 ± 0.10 (P <0.001). Concomitantly, specific binding of [125I]SMC to 50 x 106 mononuclear cells/ml fell from 13.61 ± 0.97{\%} to 10.40 ± 0.85{\%} (P <0.02). The decrease in specific binding was predominantly secondary to a reduced number of SMC receptor sites per cell, with no alteration in receptor affinity. Overall, a significant inverse correlation was observed between plasma SM levels and mononuclear cellular binding of [125I]SMC (P <0.001). The data demonstrate that treatment of hypopituitary dwarfs with conventional therapeutic doses of human GH results in significant acute increases in plasma SM levels in the majority of subjects, with a reciprocal decline in the specific binding of [125I]SMC. We conclude that SM, like insulin, is capable of regulating homologous receptor concentrations under both in vitro and in vivo conditions.",
author = "Rosenfeld, {Ronald (Ron)} and Kemp, {S. F.} and S. Gaspich and Hintz, {R. L.}",
year = "1981",
language = "English (US)",
volume = "52",
pages = "759--764",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - In vivo modulation of somatomedin receptor sites

T2 - Effects of growth hormone treatment of hypopituitary children

AU - Rosenfeld, Ronald (Ron)

AU - Kemp, S. F.

AU - Gaspich, S.

AU - Hintz, R. L.

PY - 1981

Y1 - 1981

N2 - We have previously demonstrated that somatomedin (SM) can induce the loss of specific SMC receptors on cultured IM-9 lymphocytes in a time- and concentration-dependent manner. To investigate the acute regulation of SM binding under in vivo conditions, we have evaluated SM receptors on circulating mononuclear cells obtained from 12 hypopituitary dwarfs before and after 4 days of human GH administration (0.1 U/kg.day). Plasma SM levels, measured by radioreceptor assay, rose from 0.37 ± 0.08 U/ml (mean ± SEM) to 1.00 ± 0.10 (P <0.001). Concomitantly, specific binding of [125I]SMC to 50 x 106 mononuclear cells/ml fell from 13.61 ± 0.97% to 10.40 ± 0.85% (P <0.02). The decrease in specific binding was predominantly secondary to a reduced number of SMC receptor sites per cell, with no alteration in receptor affinity. Overall, a significant inverse correlation was observed between plasma SM levels and mononuclear cellular binding of [125I]SMC (P <0.001). The data demonstrate that treatment of hypopituitary dwarfs with conventional therapeutic doses of human GH results in significant acute increases in plasma SM levels in the majority of subjects, with a reciprocal decline in the specific binding of [125I]SMC. We conclude that SM, like insulin, is capable of regulating homologous receptor concentrations under both in vitro and in vivo conditions.

AB - We have previously demonstrated that somatomedin (SM) can induce the loss of specific SMC receptors on cultured IM-9 lymphocytes in a time- and concentration-dependent manner. To investigate the acute regulation of SM binding under in vivo conditions, we have evaluated SM receptors on circulating mononuclear cells obtained from 12 hypopituitary dwarfs before and after 4 days of human GH administration (0.1 U/kg.day). Plasma SM levels, measured by radioreceptor assay, rose from 0.37 ± 0.08 U/ml (mean ± SEM) to 1.00 ± 0.10 (P <0.001). Concomitantly, specific binding of [125I]SMC to 50 x 106 mononuclear cells/ml fell from 13.61 ± 0.97% to 10.40 ± 0.85% (P <0.02). The decrease in specific binding was predominantly secondary to a reduced number of SMC receptor sites per cell, with no alteration in receptor affinity. Overall, a significant inverse correlation was observed between plasma SM levels and mononuclear cellular binding of [125I]SMC (P <0.001). The data demonstrate that treatment of hypopituitary dwarfs with conventional therapeutic doses of human GH results in significant acute increases in plasma SM levels in the majority of subjects, with a reciprocal decline in the specific binding of [125I]SMC. We conclude that SM, like insulin, is capable of regulating homologous receptor concentrations under both in vitro and in vivo conditions.

UR - http://www.scopus.com/inward/record.url?scp=0019737644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019737644&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 759

EP - 764

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -